Home›Stocks›BMRN

BMRN — structural market context

BioMarin Pharmaceutical Inc. C

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 16. Each line shows the earlier value, the later value and their dates.

Price

Close $54.68 (Oct 16) vs $56.05 (Oct 15): −2.44%.

Volume

1.11× its 20-session average (2.4M) on Oct 16.

Includes pre- and post-market trading.

Short interest

Short interest 11.5M shares (settlement Sep 30) vs 10.1M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 4 days with fails, largest 23K shares on Sep 18.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 1 day with fails, largest 48K shares on Sep 2.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

BMRN short interest & days to cover

SHARES SHORT
11.5M
% OF FLOAT
—
DAYS TO COVER
5.5
CHANGE VS PRIOR
+14.4%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (18d ago)

BMRN fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-30 · 18d260$59.87
2026-09-21 · 27d823$63.94
2026-09-18 · 30d23K$65.08

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

BMRN insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 1 sale

InsiderTypeSharesValueFiled
Davis George Eric · officer: EVP, Chief Legal OfficerSell (S)18K$1.2M2026-09-03

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

BMRN analyst ratings

FirmActionRatingPublished
BarclaysholdOverweight2026-10-14
Barclaysprice_target—2026-10-14
BMO CapitalholdOutperform2026-09-16
BMO Capitalprice_target—2026-09-15
Cantor Fitzgeraldprice_target—2026-09-01

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

Are insiders buying BMRN?
In the last 12 months of SEC Form 4 filings, BMRN recorded 0 insider purchases and 1 sale reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about BMRN?
The most recent action: Barclays hold to Overweight on 2026-10-14. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell BMRN?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with B

B · Barrick Mining CorporationBAM · Brookfield Asset Management LtBAND · Bandwidth Inc.BBNX · Beta Bionics, Inc.BE · Bloom Energy CorporationBEAM · Beam Therapeutics Inc.All B →

BMRN: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.